药物组合可能对卵巢癌有效。 - Suppr

Suppr

超能文献

Drug combo may be effective in ovarian cancer.

出版信息

Cancer Discov. 2014 Aug;4(8):OF8. doi: 10.1158/2159-8290.CD-NB2014-089. Epub 2014 Jun 5.

DOI:10.1158/2159-8290.CD-NB2014-089

PMID:25092763

Abstract

摘要

相似文献

Drug combo may be effective in ovarian cancer.

Cancer Discov. 2014 Aug;4(8):OF8. doi: 10.1158/2159-8290.CD-NB2014-089. Epub 2014 Jun 5.

Cediranib aims for a comeback.

J Natl Cancer Inst. 2015 Mar 5;107(3). doi: 10.1093/jnci/djv068. Print 2015 Mar.

Combining targeted therapies in ovarian cancer.

Lancet Oncol. 2014 Oct;15(11):1179-81. doi: 10.1016/S1470-2045(14)70421-8. Epub 2014 Sep 10.

PARP inhibitors in BRCA mutation-associated ovarian cancer.

Lancet Oncol. 2015 Jan;16(1):10-2. doi: 10.1016/S1470-2045(14)71172-6. Epub 2014 Dec 4.

Maintenance olaparib in advanced ovarian cancer.

Lancet Oncol. 2018 Dec;19(12):e671. doi: 10.1016/S1470-2045(18)30816-7. Epub 2018 Oct 25.

Actualities in Ovarian Cancer in the Perspective of 2015 (ASCO and ECCO).

Chirurgia (Bucur). 2016 Jan-Feb;111(1):9-11.

Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer.

Gynecol Oncol. 2011 May 1;121(2):426. doi: 10.1016/j.ygyno.2010.11.049. Epub 2011 Feb 15.

Mechanism of Cediranib-Olaparib Combo Revealed.

Cancer Discov. 2019 Aug;9(8):990-991. doi: 10.1158/2159-8290.CD-NB2019-064. Epub 2019 Jun 10.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.

Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.

Nanomedicine. 2012 Aug;8(6):891-9. doi: 10.1016/j.nano.2011.10.014. Epub 2011 Nov 16.

引用本文的文献

Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.

Cancer Prev Res (Phila). 2013 Oct;6(10):1074-83. doi: 10.1158/1940-6207.CAPR-13-0157. Epub 2013 Aug 20.

Deciphering the role of stroma in pancreatic cancer.

Curr Opin Gastroenterol. 2013 Sep;29(5):537-43. doi: 10.1097/MOG.0b013e328363affe.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Drug combo may be effective in ovarian cancer.

Cancer Discov. 2014 Aug;4(8):OF8. doi: 10.1158/2159-8290.CD-NB2014-089. Epub 2014 Jun 5.

Cediranib aims for a comeback.

J Natl Cancer Inst. 2015 Mar 5;107(3). doi: 10.1093/jnci/djv068. Print 2015 Mar.

Combining targeted therapies in ovarian cancer.

Lancet Oncol. 2014 Oct;15(11):1179-81. doi: 10.1016/S1470-2045(14)70421-8. Epub 2014 Sep 10.

PARP inhibitors in BRCA mutation-associated ovarian cancer.

Lancet Oncol. 2015 Jan;16(1):10-2. doi: 10.1016/S1470-2045(14)71172-6. Epub 2014 Dec 4.

Maintenance olaparib in advanced ovarian cancer.

Lancet Oncol. 2018 Dec;19(12):e671. doi: 10.1016/S1470-2045(18)30816-7. Epub 2018 Oct 25.

Actualities in Ovarian Cancer in the Perspective of 2015 (ASCO and ECCO).

Chirurgia (Bucur). 2016 Jan-Feb;111(1):9-11.

Gynecol Oncol. 2011 May 1;121(2):426. doi: 10.1016/j.ygyno.2010.11.049. Epub 2011 Feb 15.

Mechanism of Cediranib-Olaparib Combo Revealed.

Cancer Discov. 2019 Aug;9(8):990-991. doi: 10.1158/2159-8290.CD-NB2019-064. Epub 2019 Jun 10.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.

Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.

Nanomedicine. 2012 Aug;8(6):891-9. doi: 10.1016/j.nano.2011.10.014. Epub 2011 Nov 16.

引用本文的文献

Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.

Cancer Prev Res (Phila). 2013 Oct;6(10):1074-83. doi: 10.1158/1940-6207.CAPR-13-0157. Epub 2013 Aug 20.

Deciphering the role of stroma in pancreatic cancer.

Curr Opin Gastroenterol. 2013 Sep;29(5):537-43. doi: 10.1097/MOG.0b013e328363affe.